843 related articles for article (PubMed ID: 16536763)
1. The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Desgrandchamps F; De La Taille A; Doublet JD;
BJU Int; 2006 Apr; 97(4):727-33. PubMed ID: 16536763
[TBL] [Abstract][Full Text] [Related]
2. The Reten-World survey of the management of acute urinary retention: preliminary results.
Emberton M; Fitzpatrick JM
BJU Int; 2008 Mar; 101 Suppl 3():27-32. PubMed ID: 18307683
[TBL] [Abstract][Full Text] [Related]
3. Prostate size influences the outcome after presenting with acute urinary retention.
McNeill AS; Rizvi S; Byrne DJ
BJU Int; 2004 Sep; 94(4):559-62. PubMed ID: 15329112
[TBL] [Abstract][Full Text] [Related]
4. Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Tiong HY; Tibung MJ; Macalalag M; Li MK; Consigliere D
Urol Int; 2009; 83(1):44-8. PubMed ID: 19641358
[TBL] [Abstract][Full Text] [Related]
5. Management of acute urinary retention: a worldwide survey of 6074 men with benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F; Adjali K; Gomez Guerra L; Hong SJ; El Khalid S; Ratana-Olarn K;
BJU Int; 2012 Jan; 109(1):88-95. PubMed ID: 22117624
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
McNeill SA; Hargreave TB; Roehrborn CG;
Urology; 2005 Jan; 65(1):83-9; discussion 89-90. PubMed ID: 15667868
[TBL] [Abstract][Full Text] [Related]
7. The role of alpha-blockers in the management of acute urinary retention caused by benign prostatic obstruction.
Alan McNeill S
Eur Urol; 2004 Mar; 45(3):325-32. PubMed ID: 15036678
[TBL] [Abstract][Full Text] [Related]
8. Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia.
Lucas MG; Stephenson TP; Nargund V
BJU Int; 2005 Feb; 95(3):354-7. PubMed ID: 15679793
[TBL] [Abstract][Full Text] [Related]
9. [Alpha-adrenergic blockers as a support in the treatment of acute urinary retention].
Altarac S
Lijec Vjesn; 2006; 128(7-8):233-7. PubMed ID: 17087140
[TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial on the efficacy of bladder training before removing the indwelling urinary catheter in patients with acute urinary retention associated with benign prostatic hyperplasia.
Zhengyong Y; Changxiao H; Shibing Y; Caiwen W
Scand J Urol; 2014 Aug; 48(4):400-4. PubMed ID: 24697345
[TBL] [Abstract][Full Text] [Related]
11. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
12. Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Emberton M; Elhilali M; Matzkin H; Harving N; van Moorselaar J; Hartung R; Alcaraz A; Vallancien G;
Urology; 2005 Aug; 66(2):316-22. PubMed ID: 16098361
[TBL] [Abstract][Full Text] [Related]
13. Management outcome of acute urinary retention: model of prediction.
Daly P; Connolly S; Rogers E; Sweeney P
Urol Int; 2009; 83(1):39-43. PubMed ID: 19641357
[TBL] [Abstract][Full Text] [Related]
14. Management of acute urinary retention.
Fitzpatrick JM; Kirby RS
BJU Int; 2006 Apr; 97 Suppl 2():16-20; discussion 21-2. PubMed ID: 16507048
[TBL] [Abstract][Full Text] [Related]
15. Factors predicting the success of a trial without catheter in acute urinary retention secondary to benign prostatic hyperplasia.
Bhomi KK; Bhattachan CL
Nepal Med Coll J; 2011 Sep; 13(3):178-81. PubMed ID: 22808810
[TBL] [Abstract][Full Text] [Related]
16. The efficacy of in-and-out catheterization as a way of trial without catheterization strategy for treatment of acute urinary retention induced by benign prostate hyperplasia: variables predicting success outcome.
Ko YH; Kim JW; Kang SG; Jang HA; Kang SH; Park HS; Moon du G; Cheon J; Kim JJ; Lee JG
Neurourol Urodyn; 2012 Apr; 31(4):460-4. PubMed ID: 22331691
[TBL] [Abstract][Full Text] [Related]
17. The natural history of benign prostatic hyperplasia.
Fitzpatrick JM
BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
[TBL] [Abstract][Full Text] [Related]
18. Management of acute urinary retention secondary to benign prostatic hyperplasia in the UK: a national survey.
Manikandan R; Srirangam SJ; O'Reilly PH; Collins GN
BJU Int; 2004 Jan; 93(1):84-8. PubMed ID: 14678374
[TBL] [Abstract][Full Text] [Related]
19. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
20. Results of treatment with tamsulosin in men with acute urinary retention.
Kim HL; Kim JC; Benson DA; Bales GT; Gerber GS
Tech Urol; 2001 Dec; 7(4):256-60. PubMed ID: 11763483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]